Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Lampros Papadimitriou , Charles K Moore , Javed Butler , et al Added: 4 years ago
Heart failure (HF) is a global epidemic which affects about 6 million adults in the US. It is projected that by 2030 the total cost of HF will reach US$70 billion. Despite the development of novel drugs and devices, the mortality burden of HF remains high, with one in three patients dying within 1 year of hospitalisation for HF and 40–50% within 5 years of diagnosis.1 Patients with HF are… View more

Standards & Guidelines

Heart Failure
Long-Term Survival Benefit Associated with CRT-D Compared to ICD in HF in the RAFT Trial
Added: 2 months ago Source:  Radcliffe Cardiology, Jordan Rance; Special Editor: Greg Guillory
RAFT, a new extended follow-up trial (NCT00251251) showed insight into the survival benefit associated with coronary resynchronization therapy defibrillator (CRT-D) as compared to implantable cardioverter-defibrillator (ICD) in patients with heart failure.Methodology:The Resynchronization/Defibrillation for Ambulatory Heart Failure Trial (RAFT) is a randomized trial which aimed to compare the… View more
CardioMEMS Implantation Using Gadolinium-based Contrast Agent: A Case Report
Author(s): Aniket S Rali , Lynne W Stevenson , Sandip K Zalawadiya Added: 3 years ago

Heart Failure
HF 22: DELIVER Extends Benefits of Dapagliflozin to the Full Spectrum of Pt
Author(s): Scott Solomon Added: 1 year ago
In this short interview, Dr Scott Solomon (Brigham And Women's Hospital & Harvard Medical School, Boston, MA, US) discusses the design and baseline of the DELIVER trial. This trial was designed to evaluate the effects of the dapagliflozin on cardiovascular death, heart failure (HF) hospitalization, or urgent HF visits in patients with HF with mildly reduced and preserved left ventricular ejection… View more

Heart Failure
HFA 23: MONITOR-HF: Improving QoL& Reducing HF Hospitalisations with PAP Monitoring
Author(s): Jasper J Brugts Added: 10 months ago
ESC-HFA 2023 — Dr Jasper Brugts (Thoraxcenter, NL) joins us to outline the findings and summarise the take-home messages from the MONITOR-HF trial (NTR7672). MONITOR-HF was an open-label, randomised trial, done in 25 centres in the Netherlands. Eligible patients had chronic heart failure of New York Heart Association class III and a previous heart failure hospitalisation, irrespective of… View more

Heart Failure
Impact of Iron Deficiency in Heart Failure
Author(s): Josep Comin-Colet Added: 9 years ago

Heart Failure
HFA 23: Trientine-HCL for Treatment of HFrEF
Author(s): James L Januzzi , Harriette Van Spall Added: 10 months ago
ESC-HFA 2023 - Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr James Januzzi (Massachusetts General Hospital, US) to discuss the findings of the TRACER-HF trial. Trientine-HCL is an oral chelation agent. Preclinical trials suggest that this promotes a reverse cardiac remodelling effect in HFrEF patients. 200 patients with New York Heart Association Class II or… View more

Heart Failure
Author(s): Tonje Thorvaldsen , Lars H Lund Added: 3 years ago
Heart failure (HF) is associated with poor quality of life, high risk of death and is the leading cause of hospitalisation.1 With an ageing population and improved care for cardiovascular diseases, the prevalence of HF is increasing. Despite advances in HF therapies, 1–10% of the population with HF progress to an advanced stage of the disease.2,3 In the US, an estimated 250,000–300,000 patients… View more

Heart Failure
Why is Iron Deficiency Recognised as an Important Comorbidity in Heart Failure?
Author(s): Nicole Ebner , Stephan Von Haehling Added: 3 years ago
Iron is an essential trace element that is present in a number of molecular systems, and it is increasingly recognised as an important cofactor for a variety of cell systems.1 It has been acknowledged that iron plays an important role in oxygen transport, as well as in cell growth and proliferation. In recent years, more insight has been gained into iron physiology and the regulation of cellular… View more

Heart Failure
Foreword

Article

Author(s): Andrew JS Coats , Giuseppe Rosano Added: 3 years ago
It is with great pleasure that we introduce to you, our readers, to volume 5, issue 2 of Cardiac Failure Review. This issue we are focusing on clinical syndromes and the impact and therapy of selected comorbidities commonly seen in the heart failure (HF) patient. Stolfo and Savarese take another look at the landmark trials of angiotensin-converting enzyme (ACE) inhibitors in HF from the… View more

Heart Failure